Repligen (NASDAQ:RGEN) Earns Overweight Rating from Analysts at Wells Fargo & Company
Wells Fargo & Company started coverage on shares of Repligen (NASDAQ:RGEN – Free Report) in a research note published on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $180.00 price target on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on RGEN. Benchmark restated a hold rating […]
More Stories
Tactile Systems Technology (NASDAQ: TCMD) Appoints Laura G. King to Board of Directors
Tactile Systems Technology, Inc. recently announced the election of Laura G. King to its board of directors on January 10,...
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Receives “Outperform” Rating from Wedbush
Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research report issued...
Wearable Devices Ltd. (NASDAQ:WLDS) Sees Large Decline in Short Interest
Wearable Devices Ltd. (NASDAQ:WLDS – Get Free Report) was the recipient of a significant decline in short interest in December....
Stratus Properties (NASDAQ:STRS) Share Price Crosses Below 200 Day Moving Average – Should You Sell?
Stratus Properties Inc. (NASDAQ:STRS – Get Free Report)’s stock price passed below its 200-day moving average during trading on Tuesday...
LightInTheBox (NYSE:LITB) Share Price Passes Below Two Hundred Day Moving Average – What’s Next?
LightInTheBox Holding Co., Ltd. (NYSE:LITB – Get Free Report) shares passed below its two hundred day moving average during trading...
H2O Innovation (CVE:HEO) Share Price Passes Below 200 Day Moving Average – What’s Next?
H2O Innovation Inc. (CVE:HEO – Get Free Report) crossed below its two hundred day moving average during trading on Tuesday...